Tyree v. Boston Scientific Corp.
56 F. Supp. 3d 826
S.D.W. Va2014Background
- This MDL involves transvaginal mesh devices used for pelvic organ prolapse and stress urinary incontinence; over 60,000 cases across MDLs, with 13,000 in MDL 2326.
- In this case, four consolidated plaintiffs received the Obtryx Transobturator Mid-Urethral Sling System (Obtryx) implanted in West Virginia.
- Plaintiffs allege various theories including negligence, design and manufacturing defects, failure to warn, warranties, and punitive damages; some related claims have been dismissed.
- Boston Scientific Corporation (BSC) moved in limine to preclude any evidence or argument that it owed or breached a duty to directly warn plaintiffs about Obtryx risks.
- Judge Goodwin granted BSC’s Motion in Limine No. 9, determining the learned intermediary doctrine applies to this medical device case under West Virginia law.
- The court analyzed Karl and its narrow interpretation, distinguishing this case as involving a medical device with no direct-to-consumer advertising, so the learned intermediary doctrine controls evidence of direct warnings.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Is Karl controlling, narrowing or excluding the learned intermediary doctrine in this device case? | Karl narrows or rejects the doctrine for drugs with DTC advertising; device context unclear. | Karl applies broader restrictions to drug manufacturers; device context should preserve the learned intermediary doctrine. | Karl does not govern; learned intermediary applies to this medical device case. |
| Does absence of direct-to-consumer advertising affect the doctrine’s applicability? | Karl’s rationale about DTC advertising should not be dispositive here. | Karl’s logic hinges on DTC; absence supports applying the doctrine. | Absence of DTC advertising supports applying the learned intermediary doctrine. |
| Can medical device manufacturers rely on learned intermediary to limit warning duty to treating physicians? | Pati ents rely on direct warnings regardless of device type. | Treating physician as intermediary suffices; direct warnings to patients not required. | Yes; warning duty limited to treating physicians for this device case. |
| Should the court exclude any argument that BSC owed or breached a direct warning to plaintiffs? | Direct warnings to patients were at issue. | Duty to warn to patients was not applicable under Karl. | GRANTED; evidence of direct patient warnings is irrelevant. |
Key Cases Cited
- Karl v. Janssen Pharmaceuticals, 647 S.E.2d 899 (W.Va. 2007) (rejects learned intermediary for drug manufacturers in DTC context; informs scope of warning duty)
- Perez v. Wyeth Labs., Inc., 734 A.2d 1245 (N.J. 1999) (discusses direct-to-consumer advertising and physician–patient warning dynamics)
- Marks v. United States, 430 U.S. 188 (U.S. 1977) (narrowest-ground approach for fragmented opinions)
- Beale v. Biomet, Inc., 492 F.Supp.2d 1360 (S.D. Fla. 2007) (supports applying learned intermediary to implants; physician’s role emphasized)
- Woodcock v. Mylan, Inc., 661 F.Supp.2d 602 (S.D. W.Va. 2009) (distinguishes choice-of-law context; Karl analysis not bound by Woodcock)
- Roney v. Gencorp, 654 F.Supp.2d 501 (S.D. W.Va. 2009) (Karl’s context-specificity; limits applicability to drugs with DTC)